Who else is counting down the days til the Daily Mushroom + Entheon Biomedical Mental Health Town Hall?? If you haven’t registered yet, you can do so here. What are you waiting for? It’s totally free and virtual so anyone can attend.
Here’s what’s in store for you in today’s issue:
🍄 The psychedelic that’s already in our brains
🍄 MAPS receives Innovation Passport for MDMA therapy 🎉
🍄 First commercial study of LSD in 40 years
🍄 Will Oregon legalize microdosing?
🍄 And more.
In this episode of The Daily Mushroom Podcast, we have Cory Firth, Executive Director of The Canadian Psychedelic Association and founder of DoseDay! Cory opens about his battle with mental health and shares his experience with psychedelics in his quest to find meaning in his life. He also talks about how he got himself into a 7 ayahuasca retreat and what that journey gave him.
MindMed’s LSD-based compound received FDA clearance, allowing the company to proceed with a trial that will be the first commercial study of LSD in over 40 years.
The study will assess 200 patients with generalized anxiety disorder to find the optimal dose of the formulation.
Shares of MNMD spiked 30% following the announcement 💰
A recent study found pure MDMA administered in a clinic does not have the “come down” effect that recreational users often report the day after dosing.
Participants maintained a positive mood during the week following the dose. Plus, no participant had used or desired to use illegal MDMA at the 3 month and 6 month follow ups.
The iconic red and white spotted mushroom (officially called Amanita Muscaria and unofficially called the Super Mario mushroom) is showing potential to treat arthritis.
Psyched Wellness (PSYC) is working with the National Research Council of Canada (NRC) to study the mushroom’s properties. It doesn’t contain psilocybin, but has a different psychoactive component called muscimol.
Preliminary data suggests that Amantia Muscaria could reduce inflammation in the skin, gut, brain, and lungs. The company believes it has potential to treat chronic inflammatory conditions like arthritis.
Maybe that’s why Mario can jump so high without destroying his joints 😉
The Innovation Passport will make MDMA therapy for PTSD widely available in the UK, as rapidly as possible!
The Multidisciplinary Association for Psychedelic Studies (MAPS) found that 88% of patients had a reduction in PTSD symptoms after three MDMA sessions in conjunction with trauma-focused therapy.
The organization was granted an Innovation Passport for the treatment – a UK designation that speeds up the timeline for approval of innovative medicines for life-threatening conditions (similar to Breakthrough Therapy Designations in the US, which the treatment received in 2017).
Did you know that one of the most promising addiction treatments is a psychedelic compound that’s found throughout nature and is present within the human body?
It’s called DMT (N,N-Dimethyltryptamine) and is thought to be produced in the brain’s pineal gland. DMT is released in large amounts when we dream and when we die.
Learn what leading DMT experts have discovered at the Daily Mushroom + Entheon Biomedical Mental Health Town Hall on Thursday, Feb. 3rd. Register now for free to get the inside scoop 👇
CCrest Laboratories is donating psilocybin truffles so patients in need can access the medicine for free through Canada’s Special Access Program (SAP).
The company was just approved as a licensed psilocybin producer by Health Canada, along with Numinus Wellness (NUMI) and Filament Health’s (FH) Psilo Scientific, allowing them to supply psilocybin for clinical trials and emergency treatments through the SAP.
The truffles will be grown by Red Light Holland (TRUFF) and tested at CCrest Labs before being donated as part of their “compassionate need and free supply” approach.
Beckley Psytech began training psychotherapists for a phase II study on 5-MeO-DMT for treatment-resistant depression through Fluence’s interactive training program. Within the next year, Beckley aims to train 80 psychotherapists on how to administer psychedelic therapy.
Mydecine (MYCO) is partnering with a UK-based charity called Combat Stress and the King’s College London to study psilocybin therapy as a treatment for veterans with severe, treatment-resistant PTSD.
Psygen Labs entered into an agreement to supply Universal Ibogaine (IBO) with ibogaine for an upcoming clinical trial on opioid addiction.
atai Life Sciences (ATAI) launched a wholly owned platform company called Invyxis, which will focus on developing novel compounds that target serotonin 5-HT2A receptors.
Akome Biotech, a subsidiary of Core One Labs’ (COOL), signed a consulting agreement with the University of Barcelona to develop psychedelic treatments for depression, stroke, Parkinson’s, and Alzheimer’s.
Ketamine One (MEDI) changed its name to Wellbeing Digital Sciences and partnered with Nova Mentis (NM) to study psilocybin microdosing for fragile x syndrome.
But one question remains unanswered: will the new program include microdosing?
For the past year, the Oregon Health Authority has been planning the regulatory framework to implement Measure 109, which legalized psilocybin sessions under the care of licensed facilitators. The program is on schedule to roll out at the beginning of 2023.
At the latest public Zoom meeting, a push to include microdosing in the program received backlash from some advisory board members, but others thought it was worth considering. Members have until the end of June to reach a consensus.
The first bill would promote research focused on treating depression and anxiety in veterans. The second would promote research into 10 different conditions and reduce the penalty for psilocybin possession to a fine.
